Orally disintegrating tablet of dehydroepiandrosterone and/or combination of dehydroepiandrosterone and l-theanine

FIELD: medicine.

SUBSTANCE: invention represents a biologically active composition in the form of an orally disintegrating tablet characterised by the fact that it contains dehydroepiandrosterone (DHEA) as an active component, or its combination with theanine, and inert filling agents: mannitol, sorbitol, maltitol, crospovidone, copovidone, a lubricant, an intensive sweetening agent and a flavouring agent in certain mixture ratio.

EFFECT: composition is stable and has high bioavailability.

4 cl, 3 ex


The invention relates to the field of pharmaceutical and food industry.

Dehydroepiandrosterone (DHEA, DHEA) is a multifunctional steroid hormone, secreted by the adrenal glands the adrenal glands and affect androgen receptors.

L-Theanine (L-Theanine, L-Theanine) is an amino acid derived from tea leaves, natural antioxidant, actively penetrates into the brain through the blood-brain barrier and exerts psychoactive properties: reduces stress, improves cognitive abilities and improves mood, has anticonvulsant activity; reduces blood sugar, lowers blood pressure (Nathan P, Lu K, Gray M, Oliver S (2006). "The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother 6 (2): 21-30)

In the late 80-ies of the last century it was found that this little-known at the time the hormone is directly associated with the aging process. DHEA has been found in large numbers in people under the age of puberty, and over the years, its level decreased. It is proved that DHEA prevents lipid peroxidation of cell membranes, normalizes the function of the immune system, cellular activity restores, rejuvenates the body, prevents the development of malignant tumors, improving strength and endurance of muscles, improves memory, speed Rea�tion, normalizes sexual activity, stimulates weight loss. About it, there are quite extensive clinical and experimental information.

As in women, and men DHEA plays an important role in the prevention of premature aging. It is known that over the years reduced its production, at the same time in the embryonic period it regulates energy metabolism during the growth and development of the immune system and the brain. In women, DHEA plays a crucial role in the synthesis of androgens, which decreases during menopause, which leads to the decrease of sexuality and libido.

Using the collected data about the hormone was suggested that the control of the level of DHEA at different ages and its timely adjustments can slow the onset of various disease conditions associated with old age, and to mitigate the violations associated with reduced function of the adrenal glands in men and women.

Kasson and colleagues were the first who confirmed therapeutic benefits from supplementation with dehydroepiandrosterone (DHEA) in women with reduced ovarian reserve (DOR) [Casson PR, MS Lindsay, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000; 15:2129-2132. dot: 10.1093/humrep/15.10.2129. PubMed]. They also suggested that androgen offers the potential to replace steroids postmenopausal women, in addition to estrogens [Buster JE, Cason PR Straughn AB, Dale D, Umstot ES, Chiamori N, Abraham GE. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol. 1992; 66:1163-1168-PubMed] that DHEA has immunomodulatory actions [Casson PR, Andersen RN, Herrod HG, Stentz FB, Straughn AB, Abraham GE, Buster JE. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993;169:1536-1539. PubMed].

Currently dehydroepiandrosterone available in the form of dietary supplements, such as Biolife, SciFit DHEA 200, Swanson DHEA 50mg, etc.

The main difficulty of creating effective forms for the introduction connected with the fact that DHEA is poorly soluble in water.

Known sublingual form for receiving DHEA representing the solutions or suspensions (US5407927 (A) - (1995-04-18).

A composition comprising a dehydroepiandrosterone and methods of its manufacture and application (Patent RU 2220727). In particular, discloses capsules containing 50 mg of DHEA, lactose, starch and magnesium stearate. The stability of the known compounds is achieved by a special polymorphic form of the active principle. However, such forms do not solve the problem of its rapid absorption.

Known agent having anti-hangover effect, containing as active ingredients L-serine and fructose and additionally theanine (EN 2358723 C1, 20.06.2009). The tool can be made in the form of tablets and is used as a dietary Supplement. The decision does not relate to the PR�dispersed biologically active compounds.

Known sublingual form for receiving DHEA representing the solutions or suspensions (US5407927 (A) - (1995-04-18). The liquid form does not provide acceptable organoleptic characteristics.

International patent application WO 2013012326 (A1) - 2013-01-24 describes a tablet comprising granules containing DHEA, and granules containing microcrystalline cellulose. Pills make the release of 50% of the hormone within 30 minutes.

Known tablet for buccal administration LINGUE containing 17-(1-estradiol) (0.5 mg), progesterone (200 mg), testosterone (2.0 mg) and DHEA (10.0 mg) as the active principle and excipients: silica, magnesium stearate, acacia, stevia and polyethylene glycol, flavor, wildberry. Tablets may be biologically active, nutraceutical or nutritional supplements. Buccal form requires dissolution in the mouth for 5-10 minutes (WO/2006/105615, publ. 12.10.2006). This source can be specified as the closest analogue.

The object of the invention is the creation of a new form of biologically active additives on the basis of DHEA or its combination with L-theanine.

The problem is solved solid form - orodispersible the tablet quickly disintegrating in the mouth.

A distinctive feature orodispersible form is that at the time of her appointment is not required nor drink water, nor Beriev�VAT. It decomposes in the presence of saliva, usually in a few minutes, preferably in less than one minute.

New biologically active composition in the form orodispersible tablets contains one biologically active ingredient dehydroepiandrosterone (DHEA) and the following excipients: mannitol, sorbitol, maltitol, polyplasdone, copovidone, moving substance. Intense sweetener and flavoring in the following ratio of components, wt.%:

Dehydroepiandrosterone (DHEA) 8-12%

Mannitol 69-72%

Sorbitol 1.4% to 1.8%

Maltitol of 1.0-1.4%

Polyplasdone 10-14%

Copovidone is 0.1-0.2%

Moving substance 0,5-1%

Intense sweetener 1,4-1,8%

Flavor 1-2%.

Another option of the invention is a biologically active composition in the form orodispersible tablets containing as active principle a combination of L-theanine with Dehydroepiandrosterone (DHEA) and excipients: mannitol, sorbitol, maltitol, polyplasdone, copovidone, a moving substance, intense sweetener and flavoring in the following ratio of components, wt.%:

Dehydroepiandrosterone (DHEA)3-35%
Mannitol 39-75%
Sorbitol0.4 to 5.8%
CopovidoneOf 0.1-0.2%
Moving substanceOf 0.1-5%
Intense sweetenerOf 0.4% to 3.8%
FlavoringOf 0.1-5%

The inclusion of theanine in the composition provides a potentiation of energy and hormone potential Dehydroepiandrosterone.

As a sliding agent may be selected starch, talc, kaolin, bentonites, silica. Most preferably, the use of silicon dioxide, colloidal anhydrous.

As the Intense sweetener may be selected from aspartame, Acesulfame potassium, saccharin, stevioside and the like, and mixtures thereof. Most preferably, the use of aspartame.

The flavoring is selected from the acceptable food flavorings type "forest fruits" or "tropical blend".

The invention is illustrated by the following examples.

Example 1

Each Town�sperna Tablet (Dehydroepiandrosterone (DHEA) - 25 mg) contains:

Dehydroepiandrosterone (DHEA)10%The active substance

Inert fillers

Mannitol177.8 mg71.12%Solvent, sweetener
Sorbitol4.0 mg1.6%The binder component
Maltitol2.9 mg1.16%Sweetener
Polyplasdone30.8 mg12.32%Dezintegriruetsja component
Copovidone0.4 mg0.16%The binder component
Silica, colloidal anhydrous2.1 mg0.84%Moving substance
Aspartame4.0 mg 1.6%Sweetener
Flavor "forest fruits"3.0 mg1.2%Flavoring
The total number of250.0 mg100%

Example 2 a Method of manufacturing

The manufacturing process consists of seven main steps: (1) control of starting materials and primary packaging (2) weighing, (3) filtration, (4) mixing, (5) pressing, (6) packing and (7) control of the final product. Lot size: (360.000 kg=1440000 tablets (250 mg each).

Step 1. Control of starting materials and primary packaging

All released raw materials and primary packaging double-checked using quality Control of Chemicals.

Step 2. Weighing of raw materials

Step 3. Sifting through a strainer (0.5±0.05 mm)

All weighted material is sifted through a strainer to ensure no clumps, which are formed during storage.

Step 4. Mixing

Equipment: mixer Servolift MC (capacity maximum mixing drum 500 kg) - diffusion mixer

The order of addition to the mixing drum:

1. DHEA - 36.000 kg

2. Aspartame - 5.760 kg

3. Aromatized�R forest fruits Of 4,320 kg

4. Copovidone - 0.576 kg

5. Silica, colloidal anhydrous - 3.024 kg

6. Maltitol - 4.176 kg

7. Sorbitol - 5.760 kg

8. Polyplasdone - 44.352 kg

9. Mannitol - 256.032 kg.

The mixing process was conducted at a mixing speed of 11 rpm for 50 minutes.

Step 5. Pressing

Equipment: rotationy tablet press for pressing tablets KILIAN S250 SMART

The method used for the manufacture of tablets is direct compression using a rotary tablet press.

The parameters are the following:

Appearance - white round tablet with a flat upper surface with beveled edges

Weight - 20 tablets 5.0 g ± 5%

The average weight of tablets - 250 mg ± 5%

Height tablets - 3.4±0.5 mm

Hardness is not more than 50 N

Step 6. Packaging

1. The bottle of pills marked in primary packaging: plastic containers and caps, 30 tablets each.

2. Packaging is one of the primary packaging leaflets with packaging in cardboard boxes.

Step 7. End-product control

The disintegration timeNot more than 2 minutes

Example 3

Dehydroepiandrosterone (DHEA)3%
The raspberry flavoring0,1%

The disintegration time is not more than 3 minutes.

The composition is prepared in the sequence of example 2, where theanine mixed with DHEA.

Indications for use of trains:

- Stress and depression (increases stress resistance of the organism).

- Obesity (DHEA normalizes the fat content in muscles occurs weight loss without loss of appetite).

- Prevention of tumors (including cancer).

- Cardiovascular disease (halve the death rate from cardiovascular disease).

- Memory loss and Alzheimer's disease (protects brain cells from a number of degenerative diseases).

- Sports nutrition.

- Osteoporosis (increases bone density and prevents osteoporosis � women and men).


Is multiple sclerosis.


- Normalization of hormonal levels in men, increases sexual activity and the Genesis of sperm) and women (delays the onset of menopause).

- Prevents premature aging.

- Involution and any signs of involutional disorders, including immune system and diseases associated with involution of the organism.

1. Biologically active composition in the form orodispersible tablet, which contains dehydroepiandrosterone (DHEA) as an active ingredient and excipients: mannitol, sorbitol, maltitol, polyplasdone, copovidone, a moving substance, intense sweetener and flavoring in the following ratio of components, wt.%:

Dehydroepiandrosterone (DHEA)8-12
MaltitolOf 1.0-1.4
Moving substance0,5-1
Intense sweetener1,4-1,8

2. Biologically active composition in the form orodispersible tablets, characterized in that it contains a combination of dehydroepiandrosterone (DHEA) with L-theanine as an active ingredient and excipients: mannitol, sorbitol, maltitol, polyplasdone, copovidone, a moving substance, intense sweetener and flavoring in the following ratio of components, wt.%:

Dehydroepiandrosterone (DHEA)3-35
Moving substanceOf 0.1-5
Intense sweetener0,4-3,8
Flavoring Of 0.1-5

3. The composition according to claim 1, characterized in that it contains as a moving substance silica colloidal anhydrous.

4. The composition according to claim 1, characterized in that it contains as an intense sweetener aspartame.


Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely represents a method for producing an orally disintegrating tablet. The tablet is prepared by the method involving the stages of providing a liquid containing a drug substance, presenting a solid element having an at least one cavity formed thereof, cooling the solid element down to a temperature below a chilling temperature of the liquid, filling the cavity with the liquid, hardening the liquid in the cavity, rejecting heat from the liquid through a cavity wall by conductive heat transfer to form a solid granule containing a drug substance, with no active profiling along the whole surface of the granule, removing the granule from the cavity and drying the granule in vacuum.

EFFECT: developing the method for producing the orally disintegrating tablet.

15 cl, 4 ex, 6 tbl, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely, represents a delivery system for the application in the oral cavity, application and method of obtaining the said delivery system. The delivery system includes a carrier, which includes a cellulose-based or starch-based material and has a surface, including oxygen-binding sites and one binding unit, bound to the carrier, where the said binding unit includes a sugar chain of the following formula: xylose-galactose-galactose-glucosamine.

EFFECT: realisation of the invention provides the possibility of the improved and simplified delivery of a wide range of biologically active substances, simultaneously providing a precise dose of the biologically active substance.

14 cl, 4 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a method of manufacturing a tablet by pressing a powder mixture in a press-mould plate with the formation of a tablet form, with the powder mixture including a pharmaceutically active substance and hydrated sugars, as well as exposure of the tablet form to radiation for a period of time, sufficient for heating the hydrogen-containing material in the tablet form to a temperature higher than its dehydration temperature with the tablet formation.

EFFECT: increase of production efficiency.

21 cl, 14 dwg, 3 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmaceutical industry, and describes a tabletted oral dosage form containing desloratadine in an amount of 3 to 15%, processing additives and a pharmaceutically acceptable excipient. The processing additives consist of sodium croscarmellose, magnesium stearate and povidone. The excipient represents a mixture of lactose disaccharide and microcrystalline cellulose polysaccharide in ratio from 2:1 to 8:1. Lactose and microcrystalline cellulose have an average particle size from 30 to 200 mcm. Producing the table involves granulating desloratadine, lactose and microcrystalline cellulose.

EFFECT: invention provides reducing granulate compression force, increasing process capability and maintaining the high quality of the tablets.

9 cl, 4 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a formulation of a cough medical composition. The formulation of the cough medical composition contains an active substance presented by thermopsis herb powder or a dry extract of thermopsis and sodium hydrocarbonate, as well as an excipient, a granulating agent and a lubricant taken in certain relations (versions).

EFFECT: composition of the cough medical composition possesses improved pharmaceutical (appearance, taste) and technological characteristics (hardness, disintegration).

11 cl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a storage-stable pharmaceutical composition and a pharmaceutical formulation containing at least one active pharmaceutical ingredient presenting a nitrocatechol derivative, 2,5-dichlor-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide, at least one excipients and at least one binding agent, wherein at least one excipient is other than a phosphate derivative, wherein at least one binding ingredient is other than a polyvinylpyrrolidone compound, and wherein the above active pharmaceutical ingredient is present in the granulated form.

EFFECT: compositions and/or formulations according to the invention are stable for a long period of time and show a high stability if stored in the high temperature and moisture environment.

26 cl, 8 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: amlodipine base or its pharmaceutically acceptable salt, preferentially amlodipine besylate, bisoprolol fumarate, a disintegrating agent, a wetting agent, and if necessary additional excipients are homogenised; an antiadhesion agent is added, and the homogenisation procedure is continued; the homogenate is then tabletted by direct compression, or solid gelatine capsule is filled in; the prepared tablets or capsules are packed in moisture-proof protective packaging. The prepared tablets or capsules contain less than 0.5 wt % of active ingredients of compounds of formula


EFFECT: what is described is a method for preparing the stable solid pack dosage form containing the amlodipine base or its pharmaceutically acceptable salt and bisoprolol fumarate.

3 cl, 6 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to the pharmaceutical industry and provides a multilayered tablet, containing an effervescent layer, containing hydrochlorothiazide or amlodipine or its salt as an active ingredient, carbonate salt and organic acid, and a telmisartan-containing layer.

EFFECT: obtaining the multilayered tablet, containing the effervescent layer.

1 dwg, 9 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention concerns a hot-melt extruded pharmaceutical dosage form with controlled-release pharmaceutically active ingredient (A) enclosed in a matrix containing polymer (C). A core of the pharmaceutical dosage form is morphologically oriented according to the holt-melt extrusion, which is substantially orthogonal to a long direction of the dosage form; and/or a release per a unit area of the pharmacologically active ingredient (A) through a front side and an opposite back side is faster than that through an annular ring.

EFFECT: dosage form shows min breaking strength 300 H; it has an oblong shape with the long direction and the cross direction orthogonal to the long one, with the front side opposite to the back side, and the annular rim between the above front and back sides.

11 cl, 20 tbl, 3 ex, 13 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine. What is described is a pharmaceutical composition containing licarbazepine acetate, preferentially eslicarbazepine acetate, in a combination with acceptable excipients, particularly a binding agent and a disintegrating agent. What is also described is a method for wet granulation for preparing the pharmaceutical composition.

EFFECT: composition is compacted as a tablet, which has reduced size and volume density.

79 cl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, and can be used to prepare a prolonged dosage form of alprazolam. A composition contains microcapsules consisting of alprazolam, a suitable pharmaceutical carrier and a polymer matrix. A method of preparing a prolonged dosage form of alprazolam for parenteral use on the basis of poly-D,L-lactide-co-glycolide provides for preparing a primary emulsion by dissolving an active substances and an additive agent in a small volume of chloroform followed by introducing the prepared solution into an aqueous surfactant at constant stirring in a homogeniser at 20,000 rpm. Thereafter, chloroform is completely removed from the prepared primary emulsion for 24 hours; the prepared microcapsules are washed and separated by centrifugation. They are shaken with purified water to prepare the final suspension.

EFFECT: prepared composition releases the active substance for a longer period of time at a rate required to show the pharmacological action.

1 tbl

FIELD: biotechnology.

SUBSTANCE: invention relates to a biodegradable synthetic polymer, namely to the polymer of the general formula (I) , where NA has the structure: , AN has the structure: , where n is an integer >2; Z is either absent or is an amino acid residue -NH-(CH2)i-CO-, where i - is an integer from 1 to 5; D represents a linear or branched alkyl C1-C5 or benzyl; B represents a residue of aliphatic diamine -NH-(CH2)k-NH-, where k is an integer from 2 to 6; X and Y can simultaneously have the following meanings: X=H-B, Y=H, or X=Nα-(D-OCO)-L-arginyl-Z-B, Y=Nα-(D-OCO)-L-arginyl-Z, or X=R1-AN-B, Y=NA-R1, where R1 is carboxamide-alkyl of the type H2NCO-CH2- or H2NCO-CH2CH2-. Such a polymer is capable of delivering the natural L-arginine into the tissues of human, animals, through biological membranes and can be used alone or in a combination with other active compounds.

EFFECT: invention enables to obtain the polymer soluble in water, which has no cytotoxicity and enhances the level of nitrogen oxide in the tissues of humans and animals.

2 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with a method of obtaining an elongated implant, where the ratio of the diameter to the length on the implant axis constitutes between 1:20 and 1:40, for the controlled and delayed release of a GnRH analogue of triptorelin acetate. In addition, the group of inventions deals with the elongated implant, obtained in accordance with the said method.

EFFECT: group of inventions provides good control over triptorelin release from the implant.

11 cl, 26 ex, 6 dwg, 11 tbl

FIELD: medicine.

SUBSTANCE: agent for treating inflammatory periodontal and oral mucosal diseases associated with Helicobacter infection contains silicone glycerohydrogel of Si(C3H7O3)4·6C3H8O3·24H2O and bismuthate tripotassium dicitrate of formula [HOC(CH2COO)2COO]2K3Bi in the following proportions, wt %: bismuthate tripotassium dicitrate 1.0-2.5; silicone glycerohydrogel - the rest up to 100. The method of treating inflammatory periodontal and oral mucosal diseases consists in a combination of systemic standard anti-Helicobacter therapy and a local effect of the above agent on the involved region. Particularly, treating periodontitis is ensured by applying the agent on the gingival surface and introducing it into the gingival pockets once a day for 10 min; the therapeutic course makes 5-6 days. The oral mucosal diseases are treated by applying the agent 0.1 mm thick with a glass spatula on the involved oral mucosa 2 times a day; the therapeutic course is 12 days.

EFFECT: formulation of the agent provides achieving the high therapeutic effect; the dosage form is easy to be applied locally.

4 cl, 2 dwg, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and represents a sustained release solid therapeutic agent containing a combination of praziquantel with emodepside, polyvinylpyrrolidone and/or a polyvinylpyrrolidone derivative in an amount of 10 to 50 wt %, polyvinylpyrrolidone and/or the polyvinylpyrrolidone derivative is a mixture of one short-chain polyvinylpyrrolidone and one polyvinylpyrrolidone or the polyvinylpyrrolidone derivative with longer chains, and at least one excipient in an amount of 5 to 80 wt %.

EFFECT: sustained release of active substances and no lump formation in the gastrointestinal tract if two or more tablets taken.

4 cl, 7 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: therapeutic agent contains anastrozole, poly(lactic-co-glycolic acid), polyvinyl alcohol and D-mannitol. The therapeutic agent represents sub-micron particles and can be presented in the form of capsules, granules, powder, as well as a suspension for injections.

EFFECT: using the developed therapeutic agent enables achieving the therapeutic effect with lower therapeutic doses and making the antitumour therapy more comfortable for the patient.

2 cl, 1 tbl, 2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to amino amides in the bacteriochlorophyll a series, having the general formula: where n=2, 4, 8, 10, having photo-induced anti-tumour activity, and to a method for production thereof by reacting methyl ether of bacteriopheophorbide a with a diaminoalkane of formula NH2(CH2)nNH2, where n=2, 4, 8, 10, in pyridine.

EFFECT: obtaining highly efficient photosensitisers, amino amides in the bacteriochlorophyll a series based on bacteriochlorin e, having high photo-induced anti-tumour activity.

2 cl, 4 dwg, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to microencapsulation, particularly to a method for producing penicillin microcapsules. According to the method, a microcapsule coating is kappa-carageenan; a weighed amount of kappa-carageenan in acetone is added with a drug powder in the presence of the surfactant E472c; the drug to kappa-carageenan ratio at a dry basis makes from 1:1 to 1:3; after an independent solid phase is formed, carbinol 5 ml and distilled water 1 ml are added very slowly drop by drop; the prepared suspension of the microcapsules is filtered, washed and dried; the encapsulation process takes 15 minutes.

EFFECT: method provides simplifying and accelerating the penicillin microencapsulation in kappa-carageenan.

6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. There are described implanted devices with various versions of biologically active ingredient loading with the version selectable and applicable for creating a prolonged-release profile or a release profile having a low initial ejection of the biologically active ingredient from the implanted device.

EFFECT: there are described the implanted devices with various versions of biologically active ingredient loading.

11 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention represents a biologically active composition in the form of an orally dispersible tablet characterised by the fact that its contains dehydroepiandrosterone (DHEA) as an active ingredient and inert excipients: mannitol, sorbitol, manitol, crospovidone, copovidone, a lubricant, an intensive sweetener and a flavouring agent in certain proportions.

EFFECT: invention provides the new form of the biologically active additive of dehydroepiandrosterone.

3 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to biodegradable water-insoluble polyethyleneglycol-based hydrogels. The claimed invention also deals with conjugates of such biodegradable hydrogels with affinity ligands or chelating groups or ion-exchange groups, bound with carriers of prodrugs, in which a biodegradable hydrogel in accordance with the claimed invention is the carrier, and their pharmaceutical compositions, as well as to their application as a drug. Described is a biodegradable water-insoluble poly(ethyleneglycol)-based hydrogel, containing fragments of the main chain, connected by hydrolytically degradable bonds, with fragments of the main chain being characterised by the molecular weight in the range from 1 kDa to 20 kDa and having the structure C*-(A-Hyp)x, where C* represents a branching core, A represents a polymer poly(ethyleneglycol)-based chain, Hyp represents a super-branched dendrite fragment, x represents an integer number from 3 to 15; and where the superbranched dendrite fragment additionally contains reactionable functional groups and connecting functional groups, with the fragments of the main chain being connected together by means of cross-linking fragments, and each cross-linking fragment has at least two hydrolytically degradable bonds at the end. A conjugate and a bound with the carrier prodrug, containing the said biodegradable hydrogel, and the application of the prodrug in a medication are also described. Also described are: a method of obtaining the said hydrogel, which includes a stage (a) reacting of a main chain reagent, and the hydrogel, obtained by the claimed method, in the form of a coating mesh, a stent or a microparticle, obtained by crashing by mechanical methods, such as mixing, breaking, cutting pressing or milling, and sieving in case of necessity.

EFFECT: disclosed are the methods of obtaining the prodrug, the method of obtaining the prodrug, injected through the needle, and the prodrug, obtained by the claimed method.

38 cl, 41 ex, 15 dwg